IN M00005
Alternative Names: IN-C036; IN-M00005Latest Information Update: 21 Jan 2022
At a glance
- Originator HK inno.N
- Class Antihypertensives
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Hypertension
Highest Development Phases
- Phase III Hypertension
Most Recent Events
- 01 Jan 2022 Phase-III clinical trials in Hypertension in South Korea (unspecified route) (HK inno.N pipeline, January 2022)
- 25 Oct 2021 IN C036 is available for licensing as of 25 Oct 2021. http://www.inno-n.com/eng/business/out_licensing.asp (HK inno.N website, October 2021)
- 25 Oct 2021 Phase-I clinical trials in Hypertension in South Korea (unspecified route) before October 2021 (HK inno.N pipeline, October 2021)